Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 11, Pages 1409-1418
Publisher
Informa Healthcare
Online
2015-10-30
DOI
10.1517/13543784.2015.1076792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.
- (2017) S. Schuetze et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
- (2015) Patrick Schöffski et al. JOURNAL OF CLINICAL ONCOLOGY
- An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID).
- (2015) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
- (2014) I. Judson et al. CLINICAL CANCER RESEARCH
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
- (2014) Ian Judson et al. LANCET ONCOLOGY
- An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
- (2013) P. Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide
- (2013) Changhoon Yoo et al. INVESTIGATIONAL NEW DRUGS
- Cediranib for Metastatic Alveolar Soft Part Sarcoma
- (2013) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
- (2013) Gary K Schwartz et al. LANCET ONCOLOGY
- Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma
- (2012) M. M. Mita et al. ANNALS OF ONCOLOGY
- Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy
- (2012) A. Santoro et al. ANNALS OF ONCOLOGY
- An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
- (2012) M. Agulnik et al. ANNALS OF ONCOLOGY
- PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma
- (2012) A. L. Ho et al. CANCER RESEARCH
- Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
- (2012) A. Naing et al. CLINICAL CANCER RESEARCH
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)
- (2012) I. Ray-Coquard et al. ONCOLOGIST
- Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas
- (2011) Margaret von Mehren et al. CANCER
- A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas
- (2011) Scott Okuno et al. CANCER
- Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
- (2011) M. M. Gounder et al. CLINICAL CANCER RESEARCH
- Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
- (2011) F. A. L. M. Eskens et al. CLINICAL CANCER RESEARCH
- Target of Rapamycin (TOR) in Nutrient Signaling and Growth Control
- (2011) Robbie Loewith et al. GENETICS
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α
- (2010) Gaurav D. Shah et al. CANCER
- Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma
- (2010) S. Tariq Mahmood et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology
- (2010) Steven Gabardi et al. PHARMACOTHERAPY
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
- (2009) Martee L. Hensley et al. GYNECOLOGIC ONCOLOGY
- Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
- (2009) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
- (2009) Rashmi Chugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
- (2009) Robert G. Maki et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors
- (2009) Yoh Dobashi et al. MODERN PATHOLOGY
- Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
- (2008) B. I. Rini CLINICAL CANCER RESEARCH
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
- (2008) Monica Mita et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started